- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02432378
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
A PHASE 1-2 NEOADJUVANT DOSE FINDING, SAFETY, AND IMMUNOLOGIC EFFICACY TRIAL OF INTENSIVE LOCOREGIONAL CHEMOIMMUNOTHERAPY FOR RECURRENT OVARIAN CANCER AND TUMOR-SPECIFIC INTRANODAL AUTOLOGOUS ALPHA-DC1 VACCINES
This study will evaluate the immunologic and potential clinical effectiveness of intensive locoregional sequential intraperitoneal (IP) cisplatin (IPC) with intravenous (iv) paclitaxel followed by peritoneal infusion of a chemokine modulatory (CKM) regimen composed of a cocktail of IP rintatolimod and interferon-alpha (IFNα) for patients with advanced stage ovarian cancer (III-IV) at primary neoadjuvant setting.
In the safety phase I phase, we determined the tolerable dose of IPC-CKM. In this phase 2 we will add intradermal (ID) autologous αDC1 vaccines (known to be nontoxic) to the tolerable IPC-CKM regimen. The effectiveness will be determined by rate of complete pathologic response.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- Hillman Cancer Center
-
Pittsburgh, Pennsylvania, United States, 15213
- UPMC CancerCenter at Magee-Womens Hospital of UPMC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must have advanced stage (III-IV) epithelial carcinoma of ovarian, tubal, or peritoneal origin.
- Histologic documentation of the original primary tumor is required via the pathology report.
- Original tumor blocks from primary diagnosis biopsy will be reviewed by our study pathologist at Magee.
- Patients must be receiving neoadjuvant chemotherapy
- Patients must be eligible for cancer-related definitive therapy with neoadjuvant chemotherapy
- Patients must be chemonaive and receiving therapy in primary first line neoadjuvant setting
- Patients must have GOG performance of 0-1
- Patients must be reasonable candidates for interval debulking surgery as well as IP platinum based combination chemotherapy regimen with no prior evidence of clinically significant intra-abdominal adhesions, persistent abdominal wall infections, renal toxicity, or bowel obstruction.
- Patients of childbearing potential must have a negative pregnancy test prior to the study entry and be practicing an effective form of contraception. If applicable, patients must discontinue breastfeeding prior to the first date of treatment on this study.
- Patient must be willing to undergo leukapheresis
- Patients must agree to appropriate clinical monitoring to receive the study regimens.
Patient must have:
- Bone marrow function:
- Absolute neutrophil count (ANC) greater than or equal to 1,500/µL, equivalent to CTCAE v4 grade 1.
- Platelets greater than or equal to 100,000/µL;
- hemoglobin greater than or equal to 8.0 g/dL.
Renal function:
- creatinine less than or equal to 1.5 x institutional upper limit normal (ULN), CTCAE v4 grade 1.
Hepatic function:
- Bilirubin less than or equal to 1.5 x ULN (CTCAE v4 grade 1).
- SGOT and alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v4 grade 1).
- Patients who have signed informed consent and authorization permitting release of personal health information.
- Patients must have a GOG Performance Status of 0 or 1.
- Exclusion Criteria:
- Patients who have an active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus (SLE), ulcerative colitis, Crohn's Disease, multiple sclerosis (MS), ankylosing spondylitis).
- Patients with a known allergy to cisplatin or taxane chemotherapy. Patients with carboplatin allergy may be included if they tolerate a test dose of IV cisplatin given in monitored floor conditions. Patients who are allergic to paclitaxel, can be alternatively treated with abraxane.
- Patients being chronically treated with immunosuppressive drugs such as cyclosporin, adrenocorticotropic hormone (ACTH), or systemic corticosteroids.
- Patients with a recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; patients who have acquired, hereditary, or congenital immunodeficiencies.
- Patients with uncontrolled diseases other than cancer will be excluded.
- Patients who are pregnant or nursing.
- Patients who have contraindications to the use of NSAID's like chronic renal failure, coronary artery disease, or bleeding ulcers.
- Patients with tumors of low malignant potential, except ovarian pseudomyxoma or with no peritoneal disease.
- Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy.
- Patients with previous pelvic radiation therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cisplatin + Celecoxib + DC Vaccine
Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
|
Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
|
Experimental: Cisplatin + CKM + Celecoxib + DC Vaccine
Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
|
Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the number of CD8+ tumor infiltrating T cells in the peritoneal fluid.
Time Frame: 8 weeks
|
The difference in CD8+ tumor infiltrating T cells over 3 cycles of platinum based chemotherapy plus immunotherapy compared with baseline.
|
8 weeks
|
Number of adverse events for the different combinations
Time Frame: 8 weeks
|
2 patients will be treated and observed for 2 cycles on each of the dose tiers to identify the acceptable dose of IFN in combination with the other protocol drugs/vaccine for the second phase of the trial.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in the number of CD3+CD8+ T cells in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of effector CD8+ T cells in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of CD4+ T cells in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of Tregs in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of myeloid-derived suppressor cells in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in the number of TH1 cells in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of natural killer cells in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of dendritic cells in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of activated macrophages in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of tumor cells in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the concentration of CCL3 in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the concentration of CCL4 in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the concentration of CCL5 in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the concentration of CXCL9 in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the concentration of CXCL10 in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the concentration of CXCL11 in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the concentration of CXCL12 in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the concentration of GrB in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the concentration of IFN gamma in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the concentration of FoxP3 in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the concentration of IDO in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the concentration of NO in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the concentration of IL-10 in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the concentration of COX-2 in the peritoneal fluid.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of CD3+ cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of CD4+ cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of CD8+ cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of CD11b+ cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of CD11c+ cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of GrB+ cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of FoxP3+ cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of IDO+ cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of CCL3 cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of CCL4 cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of CCL5 cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of CXCL9 cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of CXCL10 cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of CXCL11 cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of CCL22 cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of CXCL12 cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of GrB cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of IFN gamma cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of FoxP3 cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of IDO cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of NO cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of IL-10 cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Change in the number of COX-2 cells in the tumor tissue.
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Robert P Edwards, MD, University of Pittsburgh
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antineoplastic Agents
- Immunologic Factors
- Cyclooxygenase 2 Inhibitors
- Cisplatin
- Vaccines
- Celecoxib
Other Study ID Numbers
- 11-128
- 5P01CA132714 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Cancer
-
Roswell Park Cancer InstituteCompletedFallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditionsUnited States
-
Massachusetts General HospitalJohns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaboratorsRecruitingOvarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Eve RodlerNot yet recruitingBreast Cancer | Ovarian Cancer | Breast Neoplasm | Breast Carcinoma | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Invasive Breast Cancer | Cancer, Breast | Breast Cancer Stage III | Ovary Cancer | Malignant Tumor of Breast | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditionsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCaregiver | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Centre Leon BerardCancer Côte d'or registry; Cancer Calvados registryUnknownOvarian Epithelial CancerFrance
Clinical Trials on Cisplatin + celecoxib + DC vaccine
-
Edward HirschowitzNational Cancer Institute (NCI)CompletedVaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung CancerLung CancerUnited States
-
Radboud University Medical CenterCompleted
-
Huashan HospitalRecruiting
-
Pawel KalinskiNational Cancer Institute (NCI)CompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States
-
Baylor Research InstituteTerminatedMalignant Melanoma Stage IVUnited States
-
The Second Hospital of Shandong UniversityShandong Sunstem Biotechnology Co.,Ltd.Unknown
-
Affiliated Hospital to Academy of Military Medical...RecruitingAcute Myeloid LeukemiaChina
-
Zwi BernemanKom Op Tegen Kanker; Research Foundation Flanders; Stichting tegen KankerActive, not recruitingAcute Myeloid LeukemiaBelgium
-
University of PennsylvaniaTerminated
-
Sichuan UniversityUnknown